Are there any dosimetric advantages in using VMAT for treatment of locally advanced non-small cell lung cancer?

被引:8
|
作者
Rousseau, D. [1 ]
Autret, D. [2 ]
Krhili, S. [1 ]
Yossi, S. [1 ]
Dupas, A. [2 ]
Edouard, M. [2 ]
Mahe, M. -A. [3 ]
Giraud, P. [4 ]
Le Pechoux, C. [5 ]
Cellier, P. [1 ]
Denis, F. [6 ]
Paumier, A. [1 ]
机构
[1] Inst Cancerol Ouest, Dept Radiotherapie, F-49000 Angers, France
[2] Inst Cancerol Ouest, Unite Phys, F-49000 Angers, France
[3] Inst Cancerol Ouest, Dept Radiotherapie, F-44805 St Herblain, France
[4] Hop Europeen Georges Pompidou, Dept Radiotherapie, F-75015 Paris, France
[5] Inst Gustave Roussy, Dept Radiotherapie, F-94805 Villejuif, France
[6] Clin Victor Hugo, Ctr Jean Bernard, F-72000 Le Mans, France
来源
CANCER RADIOTHERAPIE | 2012年 / 16卷 / 07期
关键词
Non-small-cell lung cancer; Locally advanced lung cancer; Intensity-modulated radiotherapy; Volumetric modulated arc therapy; IMAT; VMAT; RapidArc (TM); INTENSITY-MODULATED RADIOTHERAPY; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; STEREOTACTIC RADIOTHERAPY; CONCURRENT CHEMOTHERAPY; RADIATION PNEUMONITIS; DOSE CONSTRAINTS; THERAPY; EXPERIENCE; MOTION; NSCLC;
D O I
10.1016/j.canrad.2012.08.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. - To analyse the dosimetric differences between the conventional conformal radiation therapy (CR) and the volumetric modulated arc therapy (VMAT) for non-small-cell locally advanced lung cancer (NSCLC). Patients and methods. - Two plans (CR and VMAT) were calculated for ten NSCLC patients. Dose to PTV, organs at risk and external contours (body), conformity index (PTV volume/volume of the 95% reference isodose) and homogeneity index ([maximal dose - minimal dose]/dose prescription) were compared. Results. - Doses delivered to PTV (homogeneity index, maximal, minimal and mean dose) are similar with both techniques but conformity index is improved by 60% with VMAT: from 0.55 +/- 0.07 with CR to 0.89 +/- 0.07 with VMAT (P = 0.002). Pulmonary protection is improved with VMAT: with CR and VMAT, respectively, the mean lung dose is 14.1 +/- 5.2 Gy and 12.2 +/- 4.5 Gy, the lung volume which receives at least 30 Gy (V30) is 20 +/- 8% and 14 +/- 5%, and the V20 is 24 +/- 11% and 20 +/- 10% (P = 0.002). The mean dose received by the body is also 9% lower (P = 0.004) and V5 is 13% higher (P = 0.004) with VMAT. V10 and V15 were similar with both modalities. From 20 Gy and higher, irradiated body volume is larger with CR than with VMAT. The relative difference increases with the dose: from 10% for 20 Gy (P = 0.014) up to 39% for 62.7 Gy (P = 0.002). Conclusion. - Compared to CR, VMAT greatly improves conformity and reduces mean dose and dose delivered from 20 Gy and higher to the lungs and the body. (c) 2012 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:619 / 626
页数:8
相关论文
共 50 条
  • [1] A dosimetric evaluation of VMAT for the treatment of non-small cell lung cancer
    Merrow, Caitlin E.
    Wang, Iris Z.
    Podgorsak, Matthew B.
    [J]. JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2013, 14 (01): : 228 - 238
  • [2] Treatment of Locally Advanced Non-Small Cell Lung Cancer
    Tam, Kit
    Daly, Megan
    Kelly, Karen
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (01) : 45 - +
  • [3] Is there a standard treatment for locally advanced non-small cell lung cancer?
    Buccheri, G
    [J]. CHEST, 1996, 109 (04) : 864 - 866
  • [4] Treatment of locally advanced non-small cell lung cancer in the elderly
    Gridelli, C
    Maione, P
    Rossi, A
    Ciardiello, F
    Raben, D
    [J]. CURRENT OPINION IN ONCOLOGY, 2005, 17 (02) : 130 - 134
  • [5] Treatment Outcome of Locally Advanced Non-small Cell Lung Cancer
    Lee, Heui Kwan
    Kwon, Hyoung-Cheol
    Lee, Sun Young
    Kim, Jung Soo
    [J]. RADIATION ONCOLOGY JOURNAL, 2006, 24 (04): : 237 - 242
  • [6] Multimodality treatment in locally advanced non-small cell lung cancer
    Trodella, L
    D'Angelillo, RM
    Ramella, S
    Granone, P
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 32 - 33
  • [7] Adaptive radiotherapy for locally advanced non-small cell lung cancer: dosimetric gain and treatment outcome prediction
    Berkovic, Patrick
    Paelinck, Leen
    Gulyban, Akos
    van Eijkeren, Marc
    Surmont, Veerle
    Lievens, Yolande
    Vandecasteele, Katrien
    [J]. ACTA ONCOLOGICA, 2017, 56 (11) : 1656 - 1659
  • [8] Dosimetric comparison of helical tomotherapy and hybrid (3DCRT-VMAT) technique for locally advanced non-small cell lung cancer
    Temelli, Oztun
    Demirtas, Mehmet
    Ugurlu, Berat Tugrul
    [J]. JOURNAL OF RADIOTHERAPY IN PRACTICE, 2021, 20 (03) : 300 - 305
  • [9] Locally advanced non-small cell lung cancer
    Pulla, MP
    Sánchez, FV
    [J]. REVISTA CLINICA ESPANOLA, 2005, 205 (08): : 392 - 394
  • [10] Chemotherapy of advanced non-small cell lung cancer: any standard treatment?
    Tonato, M
    [J]. LUNG CANCER, 2002, 37 (01) : 15 - 16